ArticleInflammation2026
ORMDL3 as Key Regulator of Endothelial Dysfunction in Atherosclerosis via Sphingolipid Biosynthesis.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ORMDL3 (ORMDL sphingolipid biosynthesis regulator 3) gene has been genetically and functionally linked to inflammatory conditions and atherosclerosis (AS). The aim of this study is to elucidate the regulatory role of ORMDL3 in endothelial inflammation, lipid homeostasis, and apoptosis within the context of AS. A recombinant adeno-associated virus (rAAV) encoding the D377Y mutant of human proprotein convertase subtilisin/kexin type 9 (rAAV/D377Y-mPCSK9) was used to induce atherosclerosis in mice and to assess the role of ORMDL3 in atherogenesis and vascular inflammation. Mechanistic studies were conducted using human umbilical vein endothelial cells (HUVECs) to evaluate the effects of ORMDL3 on endothelial inflammation, lipid metabolism, and apoptotic signaling. ORMDL3 expression was found to be elevated in aortic atherosclerotic lesions and in HUVECs exposed to pro-atherogenic stimuli. Genetic deletion of Ormdl3 in mice reduced plaque formation and vascular inflammation. In vitro, Ormdl3 knockdown suppressed the expression of adhesion molecules and proinflammatory cytokines, whereas its overexpression enhanced these responses, potentially through activation of the nuclear factor-kappa B (NF-κB) signaling pathway. ORMDL3 deficiency attenuated lipid accumulation, endoplasmic reticulum (ER) stress, and apoptosis through upregulation of ABCA1. Lipidomic profiling indicated increased ceramide and dihydroceramide levels in ORMDL3-deficient cells. Pharmacological inhibition of ceramide biosynthesis partially reversed ABCA1 upregulation, suggesting a lipid-mediated regulatory mechanism. Additionally, miR-34a-5p binds directly to ORMDL3 mRNA, downregulates its expression, and suppresses endothelial inflammation and apoptosis. Inflammatory stimulation led to downregulation of miR-34a-5p, indicating a feedback loop in ORMDL3 regulation. ORMDL3 contributed to endothelial dysfunction and plaque instability by modulating ABCA1-mediated lipid efflux, ER stress, inflammation, and apoptotic pathways. The regulatory involvement of ceramide biosynthesis and the miR-34a-5p/ORMDL3 axis provides additional insight into the molecular mechanisms underlying ORMDL3-mediated atherogenesis. Therapeutic strategies targeting ORMDL3 may enhance endothelial function and promote plaque stabilization in patients with AS. Trial RegistrationNot applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.